Table 3.
Gastrointestinal symptoms in participants with IBS, and healthy controls as assessed via visual analogue scale, at baseline and across each intervention period
| Resistant starch 2 | Sugarcane bagasse | Fibre combination | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Low | Mod | High | Low | Mod | High | Low | Mod | High | |
| IBS participants | ||||||||||
| Overalla | 18 (4−70) | 25 (19−52) | 25 (11−41) | 30 (7−36) | 19 (8−43) | 21 (2−39) | 35 (9–86) | 20 (12–34) | 30 (20−27) | 27 (21–37) |
| Abdominal paina | 13 (1−57) | 25 (11−31) | 13 (9−42) | 20 (1−41) | 17 (1–36) | 21 (3−42) | 24 (9−87) | 20 (5−33) | 29 (6−42) | 26 (3−57) |
| Bloatinga | 11 (1−75) | 30 (22−76)* | 35 (30−59)* | 35 (20−58)* | 25 (7−46) | 39 (3−50) | 38 (13−86)* | 28 (14−42) | 45 (22−55)* | 38 (25−65)* |
| Flatulence | 25 (1−64) | 27 (1−77) | 20 (2−64) | 30 (2−72) | 22 (2−73) | 9 (2−52) | 25 (2−54) | 30 (18−44) | 26 (3−59) | 25 (18−78)* |
| Satisfaction | 61 (24−70) | 35 (27−62) | 43 (22−53) | 35 (18−68) | 45 (34−74) | 51 (15−87) | 63 (17−99) | 36 (15−78) | 57 (42−66) | 47 (29−64) |
| Healthy controls | ||||||||||
| Overall | 6 (2−15) | 9 (4−20) | 10 (7−42) | 9 (6−11) | 11 (1−69) | 10 (2−55) | 11 (6−55) | 7 (3−58) | 8 (5−52) | 10 (6−27) |
| Abdominal paina | 4 (0−6) | 5 (1−18) | 14 (1−48)* | 8 (0−11)* | 10 (0−40)* | 14 (1−48)* | 10 (0−48) | 4 (1−40) | 5 (1−12) | 5 (0−11) |
| Bloatinga | 7 (3−22) | 10 (3−22) | 11 (3−38) | 7 (4−11) | 12 (2−75) | 11 (3−38) | 9 (4−38) | 5 (1−70) | 9 (3−67) | 12 (5−21) |
| Flatulencea | 13 (0−24) | 10 (4−43) | 15 (5−50) | 11 (5−14) | 4 (2−50) | 15 (5−50) | 11 (5−50) | 9 (0−77) | 10 (2−82) | 13 (0−84) |
| Satisfactiona | 9 (0−27) | 9 (1−23) | 11 (3−45) | 8 (0−47) | 12 (0−94) | 11 (0−78) | 10 (2−78) | 16 (2−70) | 10 (0−55) | 10 (0−40) |
Data are shown as median (range) and are analysed via linear mixed models. Significant differences (P ≤ 0⋅05) across the fibre doses compared with baseline are shown via asterisk.
a
Data log-transformed for analyses.